Next Article in Journal
Using a Simple Cellular Assay to Map NES Motifs in Cancer-Related Proteins, Gain Insight into CRM1-Mediated NES Export, and Search for NES-Harboring Micropeptides
Previous Article in Journal
Ribosomal RNA Modulates Aggregation of the Podospora Prion Protein HET-s
Previous Article in Special Issue
Dual Inhibition of CDK4/6 and PI3K/AKT/mTOR Signaling Impairs Energy Metabolism in MPM Cancer Cells
Review

Genomics and Functional Genomics of Malignant Pleural Mesothelioma

by 1,2 and 1,2,*
1
Izmir Biomedicine and Genome Center, Izmir 35340, Turkey
2
Department of Genome Sciences and Molecular Biotechnology, Izmir International Biomedicine and Genome Institute, Dokuz Eylul University, Izmir 35340, Turkey
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2020, 21(17), 6342; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms21176342
Received: 22 July 2020 / Revised: 20 August 2020 / Accepted: 20 August 2020 / Published: 1 September 2020
Malignant pleural mesothelioma (MPM) is a rare, aggressive cancer of the mesothelial cells lining the pleural surface of the chest wall and lung. The etiology of MPM is strongly associated with prior exposure to asbestos fibers, and the median survival rate of the diagnosed patients is approximately one year. Despite the latest advancements in surgical techniques and systemic therapies, currently available treatment modalities of MPM fail to provide long-term survival. The increasing incidence of MPM highlights the need for finding effective treatments. Targeted therapies offer personalized treatments in many cancers. However, targeted therapy in MPM is not recommended by clinical guidelines mainly because of poor target definition. A better understanding of the molecular and cellular mechanisms and the predictors of poor clinical outcomes of MPM is required to identify novel targets and develop precise and effective treatments. Recent advances in the genomics and functional genomics fields have provided groundbreaking insights into the genomic and molecular profiles of MPM and enabled the functional characterization of the genetic alterations. This review provides a comprehensive overview of the relevant literature and highlights the potential of state-of-the-art genomics and functional genomics research to facilitate the development of novel diagnostics and therapeutic modalities in MPM. View Full-Text
Keywords: malignant pleural mesothelioma; genomics; functional genomics; next-generation sequencing; RNAi and CRISPR screens malignant pleural mesothelioma; genomics; functional genomics; next-generation sequencing; RNAi and CRISPR screens
Show Figures

Figure 1

MDPI and ACS Style

Cakiroglu, E.; Senturk, S. Genomics and Functional Genomics of Malignant Pleural Mesothelioma. Int. J. Mol. Sci. 2020, 21, 6342. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms21176342

AMA Style

Cakiroglu E, Senturk S. Genomics and Functional Genomics of Malignant Pleural Mesothelioma. International Journal of Molecular Sciences. 2020; 21(17):6342. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms21176342

Chicago/Turabian Style

Cakiroglu, Ece, and Serif Senturk. 2020. "Genomics and Functional Genomics of Malignant Pleural Mesothelioma" International Journal of Molecular Sciences 21, no. 17: 6342. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms21176342

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop